Evidence map›Paper›PMID 33180184›Full record

ArticleCancer immunology, immunotherapy : CII2021

Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells.

Farsaneh Sadeghlar, Annabelle Vogt, Raphael U Mohr, Robert Mahn, Katrin van Beekum, Miroslaw Kornek, Tobias J Weismüller, Vittorio Branchi, Hanno Matthaei, Marieta Toma and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.9field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Immunobiology of cholangiocarcinoma.Journal of hepatology · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. The Functional Roles of Immune Cells in Primary Liver Cancer.The American journal of pathology · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Farsaneh Sadeghlar *Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Annabelle Vogt *Department of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Raphael U MohrDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Robert MahnDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Katrin van BeekumDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Miroslaw KornekDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Tobias J WeismüllerDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Vittorio BranchiDepartment of Visceral Surgery, University Hospital Bonn, Bonn, Germany.
Hanno MatthaeiDepartment of Visceral Surgery, University Hospital Bonn, Bonn, Germany.
Marieta TomaDepartment of Pathology, University Hospital, Bonn, Germany.
I G H Schmidt-WolfCenter for Integrated Oncology (CIO), Bonn, Germany.
Jörg C KalffDepartment of Visceral Surgery, University Hospital Bonn, Bonn, Germany.
Christian P StrassburgDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany.
Maria A González-CarmonaDepartment of Internal Medicine I, University Hospital Bonn, University of Bonn, Venusberg-Campus 1, 53105, Bonn, Germany. Maria.Gonzalez-Carmona@ukbonn.de.
University Hospital Bonn · DEUniversity of Bonn · DE

Funding

Deutsche Forschungsgemeinschaft GO 1874/1-2Deutsche Krebshilfe 109255
6 · The paper itself

Abstract

introductionGastrointestinal (GI) malignancies, such as cholangiocarcinoma, pancreatic carcinoma, and metastatic colorectal carcinoma, have a poor prognosis and effective therapeutic approaches are still challenging. Checkpoint inhibition with PD-1 or PDL-1 antibodies revealed promising results in different tumor entities; however, only few patients with GI tumors can potentially benefit from PD1/PDL1 inhibiting immunotherapy. Further immunotherapeutic strategies for GI malignancies are urgently needed. The aim of this study was to demonstrate that in vitro activation of the immune checkpoint CD40/CD40L can improve DC action towards bile duct, pancreas, and colorectal carcinoma.

methodsHuman DC were isolated from buffy coats from healthy donors, pulsed with tumor lysates and then transduced with adenoviruses encoding human CD40L (Ad-hCD40L). Using transwell assays, the effects of (m)CD40L on DC immunoactivation compared to (s)CD40L were analyzed. Surface marker and cytokine/chemokine expression were measured by flow cytometry, ELISA and cytokine arrays. Capacity of Ad-hCD40L-transduced DC to induce tumor-specific effector cells was tested using MTT proliferation assay and cytotoxicity assays. Apoptosis induction on tumor cells after culturing with supernatants of Ad-hCD40L-transduced DC was analyzed by flow cytometry.

resultsAd-hCD40L transduction induced a high expression of (s)CD40L and (m)CD40L on DC and seemed to induce a strong cellular CD40/CD40L interaction among DC, leading to the formation of cell aggregates. Due to the CD40/CD40L interaction, a significant upregulation of DC maturation markers and a Th1-shift on cytokines/chemokines in the supernatant of DC were achieved. Interestingly, a pure Th1-shift was only achieved, when a cellular CD40/CD40L interaction among DC took place. (s)CD40L induced almost no upregulation of maturation markers and rather resulted in a Th2-cytokine expression, such as IL-10. Correspondingly, (m)CD40L-expressing DC led to significant proliferation and stimulation of tumor-specific effector cells with increased cytotoxicity towards pancreatic, bile duct and colorectal tumor cells. Supernatants of Ad-hCD40L-transduced DC could also induce apoptosis in the different tumor cells in vitro.

conclusionStimulation of the immune checkpoint CD40L/CD40 by endogenous expression of (m)CD40L provokes a cellular interaction, which increases the immunomodulatory capacity of DC. A Th1 cytokine/chemokine expression is induced, leading to a significant proliferation and enabling cytotoxicity of effector cells towards human bile duct, pancreatic and colorectal tumor cells. The present data point to the promising approach for DC-based immunotherapy of gastrointestinal malignances by activating the CD40/CD40L immune checkpoint.

Indexed as

CD40 AntigensCD40 LigandCell DifferentiationCell Line, TumorCell ProliferationCholangiocarcinomaColorectal NeoplasmsCytokinesCytotoxicity, ImmunologicDendritic CellsHumansImmunotherapyLymphocyte ActivationPancreatic NeoplasmsSignal TransductionTh1 CellsCD40 AntigensCD40 LigandCytokinesCholangiocarcinomaDendritic cellsHepatocellular carcinomaImmune checkpointImmunotherapyPancreatic carcinoma

Identifiers

PMID33180184
PMCPMC8053193
OpenAlexW3099358274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.